



<http://researchspace.auckland.ac.nz>

## ***ResearchSpace@Auckland***

### **Copyright Statement**

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

### **General copyright and disclaimer**

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the [Library Thesis Consent Form](#) and [Deposit Licence](#).

### **Note : Masters Theses**

The digital copy of a masters thesis is as submitted for examination and contains no corrections. The print copy, usually available in the University Library, may contain corrections made by hand, which have been requested by the supervisor.

**The roles of growth hormone and prolactin  
in the brain during development and  
recovery from hypoxic-ischemic injury**

***Larissa Joy Christophidis, BSc(Hons)***

**A thesis submitted in partial fulfilment of the  
requirements for the degree of Doctor of Philosophy in  
Molecular Medicine, The University of Auckland, 2011**

## **Abstract**

Very preterm birth disrupts development of the brain and enhances its vulnerability to injury, resulting in neurological impairments ranging in severity from cerebral palsy to mild cognitive deficits. Currently there is no treatment available.

Unilateral hypoxic-ischemia (HI) in the three day old rat is well established as a model of brain injury in infants born at 22 to 26 gestational weeks. However, it is inherently variable. I show that this injury results in short term neurological deficits which may be capitalised upon for allocation of pups into treatment studies.

After it is injured, the brain tries to repair itself using processes that are a recapitulation of those that occur during brain development. Using a model of injury to the immature brain our laboratory has identified roles for the closely related anterior pituitary hormones growth hormone (GH) and prolactin (PRL) in the brain after injury.

Though the role of GH in neuroprotection is well demonstrated, little is known of its capacity for neuro-restoration subsequent to injury. I found that GH receptor immunoreactivity is upregulated in the ipsilateral subventricular zone at five days after injury, corresponding both spatially and temporally with injury-induced neurogenesis. Cells immunopositive for the GH receptor included proliferating and neural precursor cells and post-mitotic neuroblasts. Together with the finding from our laboratory that GH stimulates proliferation of embryonic mouse neural stem cells (NSCs), these results indicate a novel role for GH in injury-induced neurogenesis.

Whilst PRL is known to exert effects on neural progenitor and glial cells after injury to the central nervous system, its role in development of extra-hypothalamic brain regions has not been examined. Using a novel real time PCR assay I reveal the ontogeny of the long, fully functional PRL receptor isoform in the rat cerebral cortex and find that it parallels that of neurite initiation and outgrowth markers. Indeed, treatment of neurons derived from adult mouse NSCs with PRL increased the number of primary and secondary neurites. These results implicate a role for PRL in development of the cerebral cortex.

## Acknowledgements

The research performed for this thesis was a trans-Tasman effort which would not have been possible without the contribution and support of many.

From Auckland, I firstly wish to thank the instigators of this project, A/Prof. Chris Williams and Dr. Arjan Scheepens. Chris' infectious enthusiasm, optimism and keen scientific input were greatly appreciated. Arjan was a major driver of these studies who critically reviewed my work and taught me alot, from basic laboratory procedures to scientific principles. It is doubtful that this thesis would have been completed without his unwavering support and encouragement. The aforementioned, and especially Tanja Needham (née Mödersheim), Sumudu Ranasinghe and Praneeti Pathipati, unwittingly became my "adoptive family" in New Zealand, and on a personal note I would like to thank all of them for their friendship and support, as well as their scientific advice. In addition, I would like to acknowledge members of our team who joined later for their camaraderie, including Prapti Gautam and Dr. Mariella Giovannangelo; as well as Drs. Thorsten Gorba and Malin Gustavsson, who also provided help in the lab and intellectual input. Finally, I'd like to thank my latter primary supervisors; Prof. Bernhard Breier for his advice and humour, and Dr. Mhoyra Fraser for her support and getting me through to the end.

From the Centre for Hormone Research in Melbourne, I am very grateful to Prof. George Werther for allowing me to pursue my studies in Melbourne with his research group. It has been an honour and a pleasure to be a member of the team, and I'm sure I'll be a better scientist for it. For their companionship and helping me find my way in the lab, I'd like to thank Elena Andaloro, Sandra Higgins, Sheena Wong, Walid Azar and Caitlin Rowe. Above all, Dr. Vince Russo has been instrumental in the completion of my research, and it's difficult to thank him enough for all he has done. He has provided me with advice in everything from simple laboratory techniques to publishing, has been very generous with his limited amount of time, resolved any issues no matter how big or small and offered valuable critique of this thesis.

I also thank A/Prof. Ann Turnley of the Centre for Neuroscience, University of Melbourne, for allowing me to perform studies utilising mouse neural stem cells in her lab, and members of her team, particularly Alisa Turbic and Dr. Sam McLenachan, for their help with this.

Outside of the lab, the level of support provided by my husband, Manny Christophidis, has been immeasurable, and I doubt that any acknowledgement stated here can do full justice to it. Suffice to say his encouragement and motivation have enabled me to reach this point.

This thesis is dedicated to our daughter - Eleni Joy, and any brothers or sisters she may one day have – may you be as blessed to find such a fulfilling pursuit and work with such wonderful people as I have been.

***"Knowledge is an unending adventure at the edge of uncertainty"***

Jacob Bronowski, 1908 – 1974

# Table of Contents

Abstract	i
Acknowledgements	ii
Table of Contents	iii
List of Figures	vii
List of Tables	xi
List of Abbreviations	xiii
<b>1 Introduction</b>	<b>1</b>
<b>1.1 General Introduction</b>	<b>1</b>
<b>1.2 Brain injury in the preterm infant</b>	<b>2</b>
1.2.1 Incidence and Outcomes of Premature Birth	2
1.2.2 Neuropathology of hypoxic-ischemic encephalopathy in the premature infant	3
1.2.3 Aetiology of brain injury in preterm infants	8
1.2.4 Treatment for brain injury of preterm infants	13
<b>1.3 Unilateral rat brain hypoxia-ischemia models</b>	<b>13</b>
1.3.1 Animal models of hypoxic-ischemic damage in the immature brain	13
1.3.2 The P21 rat HI model	14
1.3.3 The P3 rat HI model	15
1.3.4 Importance of behavioural tests	18
<b>1.4 Mechanisms of cell death subsequent to hypoxia-ischemia</b>	<b>19</b>
1.4.1 Excitotoxicity	19
1.4.2 Oxidative stress	20
1.4.3 Neuroinflammation	23
<b>1.5 Endogenous brain repair</b>	<b>24</b>
1.5.1 Overview of neuronal development	24
1.5.2 How the brain tries to repair itself after a hypoxic-ischemic insult	26
1.5.3 Neuroprotection	28
<b>1.6 Growth factors and hormones in the brain's response to injury</b>	<b>29</b>
1.6.1 IGF-I	29
1.6.2 Growth Hormone	32
1.6.3 Prolactin	47
1.6.4 Placental Lactogen	59
<b>1.7 Aims of this thesis</b>	<b>60</b>
<b>2 Materials and Methods</b>	<b>61</b>
<b>2.1 Introduction</b>	<b>61</b>
<b>2.2 Isolation of total RNA</b>	<b>61</b>
<b>2.3 Generation of cDNA</b>	<b>62</b>
<b>2.4 Conventional reverse transcriptase PCR</b>	<b>62</b>
<b>2.5 Real time PCR</b>	<b>63</b>
<b>2.6 Extraction and purification of DNA</b>	<b>64</b>
2.6.1 Directly from PCR or restriction digest	64

2.6.2 Extraction from agarose gel	64
<b>2.7 Concentration of DNA by sodium acetate precipitation</b>	<b>65</b>
<b>2.8 Cloning into pGEM® T Easy Vector</b>	<b>65</b>
2.8.1 Ligation	65
2.8.2 Transformation	65
2.8.3 Amplification	66
2.8.4 Glycerol stock preparation	66
2.8.5 Isolation of plasmid DNA	66
2.8.6 Verification of insertion	66
<b>2.9 DNA sequencing</b>	<b>66</b>
<b>2.10 Immunohisto- and cyto- chemistry</b>	<b>67</b>
2.10.1 Delipidation and rehydration of paraffin-embedded sections	67
2.10.2 Antigen-retrieval procedure for paraffin-embedded sections	67
2.10.3 Permeabilisation of cells for immunocytochemistry	67
2.10.4 Single immunofluorescence general protocol	67
2.10.5 Double immunofluorescence- sequential protocol	68
2.10.6 Double immunofluorescence- simultaneous protocol	68
2.10.7 Multiple fluorophore imaging	69
<b>2.11 Statistics</b>	<b>69</b>
<b>3 Hypoxic-ischemia in the three day old rat brain produces short-term neurological deficits</b>	<b>70</b>
<b>3.1 Introduction</b>	<b>70</b>
<b>3.2 Materials and Methods</b>	<b>71</b>
3.2.1 Hypoxia-ischemia	71
3.2.2 Monitoring of growth	73
3.2.3 Behavioural Testing	73
3.2.4 Histological Procedure	76
3.2.5 Fluoro-Jade C staining	76
3.2.6 Scoring of Damage	77
3.2.7 Capture of images	77
3.2.8 Data Analysis	78
<b>3.3 Results</b>	<b>78</b>
3.3.1 Degenerating neurons and axons stained with Fluoro-Jade C	78
3.3.2 HI and body weight	80
3.3.3 Effect of HI on behaviour	85
<b>3.4 Discussion</b>	<b>92</b>
<b>3.5 Acknowledgements</b>	<b>98</b>
<b>4 A role for growth hormone in neuro-restoration subsequent to hypoxic-ischemic injury in the immature rat brain</b>	<b>99</b>
<b>4.1 Introduction</b>	<b>99</b>
<b>4.2 Materials and Methods</b>	<b>101</b>
4.2.1 Hypoxic-ischemic injury model	101
4.2.2 Tissue Fixation	101

4.2.3 Immunofluorescence	102
4.2.4 Scoring and semi-quantitation of GH-R immunofluorescence	103
4.2.5 Real time PCR	106
4.2.6 <i>In situ</i> hybridisation	109
4.2.7 Statistics	110
<b>4.3 Results</b>	<b>110</b>
4.3.1 Growth hormone receptor immunoreactivity is increased by hypoxic-ischemia in the immature rat brain	110
4.3.2 Neural progenitors and migratory neuroblasts in the ipsilateral SVZ are GH-R immunopositive at 5 days after HI	117
4.3.3 Relative GH-R mRNA levels in various brain regions at 5 days after HI at P21	123
<b>4.4 Discussion</b>	<b>130</b>
<b>4.5 Acknowledgements</b>	<b>137</b>
<b>5 <i>Ontogeny of gene expression of prolactin and its receptor in the early postnatal rat brain cortex and hippocampus</i></b>	<b>139</b>
<b>5.1 Introduction</b>	<b>139</b>
<b>5.2 Materials and Methods</b>	<b>141</b>
5.2.1 Collection of tissues	141
5.2.2 Dissection of hippocampus and cortex for RNA extraction	143
5.2.3 Isolation of total RNA and generation of cDNA	143
5.2.4 Primer design	143
5.2.5 Construction of a plasmid containing both PRL-R long and short transcripts	144
5.2.6 Real time PCR	150
5.2.7 Standard curve generation	151
5.2.8 Validation of the short form PRL-R and long form PRL-R standard curves	153
5.2.9 Statistics	154
<b>5.3 Results</b>	<b>155</b>
5.3.1 Validation of real time PCR assays	155
5.3.2 Total PRL-R mRNA in the early postnatal rat brain cortex and hippocampus	156
5.3.3 Validation of Standard Curves used to measure PRL-R Long form and Short form mRNA	160
5.3.4 Levels of PRL-R Long and Short form mRNA in early postnatal rat brain cortex and hippocampus	163
5.3.5 Quantitation of PRL-R Long and Short form mRNA in maternal liver and ovary	169
5.3.6 Quantitation of Long and Short form PRL-R mRNA in the P21 rat brain choroid plexus	171
5.3.7 Quantitation of PRL mRNA in the rat brain cortex and hippocampus	172
<b>5.4 Discussion</b>	<b>173</b>

<b>6</b>	<b><i>In vitro studies examining a role for prolactin in neuronal morphogenesis</i></b>	<b>182</b>
6.1	Introduction	182
6.2	Materials and Methods	183
6.2.1	Cell culture	183
6.2.2	Conventional reverse-transcriptase PCR analysis of gene expression	186
6.2.3	Immunocytochemistry	191
6.2.4	Determination of cell proliferation by MTT assay	194
6.2.5	Real time PCR	195
6.2.6	Image analysis	197
6.2.7	Statistics	199
6.3	Results	199
6.3.1	Selection of a neuronal model in which to test the effect of prolactin on neuronal differentiation	199
6.3.2	Examination of prolactin receptor expression in neuronally differentiated human neuroblastoma cells	204
6.3.3	Effect of prolactin on neuronal differentiation of cells derived from adult mouse neural stem cells	216
6.4	Discussion	224
6.4.1	Expression of PRL and its receptor by human neuroblastoma cells	226
6.4.2	Changes in hPRL-R <sub>L</sub> expression upon differentiation of human neuroblastoma cells	227
6.4.3	Effect of PRL on morphology of neurons derived from adult mouse neural stem cells	231
6.4.4	Conclusions	235
6.5	Acknowledgements	235
<b>7</b>	<b><i>Discussion</i></b>	<b>237</b>
7.1	Introduction	237
7.2	Significance of short term neurological deficits produced by hypoxic-ischemic injury to the very immature rat brain	238
7.3	Could growth hormone mediate injury-induced neurogenesis?	240
7.4	Does prolactin have a role in development of the cerebral cortex?	242
7.5	Prolactin and human neuroblastoma	245
7.6	Potential of growth hormone and prolactin to treat brain injury in the premature infant	245
7.7	Conclusions	247
	<b><i>Appendices</i></b>	<b>249</b>
A	Growth hormone induces the proliferation of neural stem cells cultured as neurospheres	249
B	The effect of inhibition of JAK/STAT signalling on growth of SK-N-MC cells	252
C	The effect of recombinant rat prolactin on proliferation of embryonic mouse neural stem cells	254
	<b><i>References</i></b>	<b>257</b>



## List of Figures

<b>Figure 1.1</b> Transverse T2 weighed FSE image of an infant at 27 weeks gestational age showing bilateral GM/IVH _____	4
<b>Figure 1.2</b> (A) Sagittal and (B) coronal T2 weighted FSE image of an infant at 27 gestational weeks, showing both GM/IVH and periventricular haemorrhage on the right in a fan shaped distribution _____	5
<b>Figure 1.3</b> A diagram of a coronal section of human cerebrum, illustrating the sites of focal and diffuse components of PVL, and the long and short penetrating arteries that supply the cerebral white matter _____	7
<b>Figure 1.4</b> Subplate Zone of a human fetus aged 25 gestational weeks _____	12
<b>Figure 1.5</b> Thionin-stained, coronal brain section from a rat that underwent 60 min (severe) hypoxia-ischemia at P21 _____	15
<b>Figure 1.6</b> Overview of nuclear migration and symmetric and asymmetric mitosis in the ventricular zone _____	25
<b>Figure 1.7</b> Schematic summary of human prefrontal cortex. At the earliest age studied (10.5 gwks) the preplate zone has been split by the early-arriving neurons of the cortical plate into neurons of the marginal zone (MZ) above and of the subplate zone (SP) below _____	26
<b>Figure 1.8</b> Primary structure of human growth hormone _____	33
<b>Figure 1.9</b> Model of JAK2 tyrosine kinase activation of the GH-R _____	35
<b>Figure 1.10</b> Diagram of GH receptor signalling pathways _____	36
<b>Figure 1.11</b> Inhibition of GH signal transduction by SOCS molecules _____	38
<b>Figure 1.12</b> Diagram illustrating the major components of GH regulation _____	39
<b>Figure 1.13</b> Primary Structure of Prolactin _____	48
<b>Figure 1.14</b> Signal transduction pathways initiated by activation of the PRL-R _____	50
<b>Figure 1.15</b> Overview of the regulation of prolactin secretion _____	54
<b>Figure 3.1</b> Photographs of a P6 rat pup undertaking the negative geotaxis test _____	74
<b>Figure 3.2</b> Photographs of a P6 rat pup during the surface righting test _____	75
<b>Figure 3.3</b> Photographs of a P6 pup performing the Elevated Body Swing Test _____	75
<b>Figure 3.4</b> Distribution of neuro-axonal loss 3 d after HI at P3, revealed by Fluoro-Jade C staining _____	79
<b>Figure 3.5</b> Neuro-axonal loss in Layers VI-VII (A, C and E) and Layer I (B, D and F) of the ipsilateral cortex 3 d after HI at P3 revealed by Fluoro-Jade C staining _____	81
<b>Figure 3.6</b> Change in weight between P3 and P6 _____	82
<b>Figure 3.7</b> Change in weight between P3 and P6 of pups in the sham group versus their control littermates _____	83
<b>Figure 3.8</b> Change in weight between P3 and P6 of control pups, pups exposed to HI and sham pups _____	85
<b>Figure 3.10</b> Box plots illustrating the time pups took complete the High Incline Negative Geotaxis test at 3 d after HI _____	88
<b>Figure 3.11</b> Box plots representing the percentage of contralateral (left) turns during the EBST at one day after HI _____	90
<b>Figure 4.1</b> Diagrams illustrating the regions of rat brain coronal sections scored for GH-R immunofluorescence _____	105
<b>Figure 4.2</b> Photomicrographs demonstrating GH-R immunofluorescence in the rat brain _____	111
<b>Figure 4.3</b> Photomicrographs illustrating GH-R immunofluorescence in various parts of the rat brain after hypoxic-ischemic injury at P21 _____	113

<b>Figure 4.4</b> Average score of GH-R immunofluorescence within each region of the cortex at 1 to 15 days after HI	114
<b>Figure 4.5</b> Average score of GH-R immunofluorescence within extra-cortical regions at 1 to 15 days after HI	115
<b>Figure 4.6</b> Photomicrographs displaying immunofluorescence for GH-R and cell markers in the ipsilateral cortex of rat brain after HI at P21	116
<b>Figure 4.7</b> Box plots representing the ratio of GH-R immunoreactivity (IR) in the right (ipsilateral) versus left (contralateral) SVZ in control animals and animals subjected to hypoxic-ischemia (HI)	117
<b>Figure 4.8</b> Photomicrographs displaying immunofluorescence for GH-R and cell markers in the ipsilateral and contralateral SVZ at 5 days after HI at P21	119
<b>Figure 4.9</b> Confocal photomicrographs displaying immunofluorescence for GH-R and Ki67 in the dorsolateral SVZ of the ipsilateral hemisphere at 5 days after HI at P21	120
<b>Figure 4.10</b> Confocal photomicrographs displaying immunofluorescence for GH-R and nestin in the ipsilateral SVZ at 5 days after HI at P21	121
<b>Figure 4.11</b> Confocal photomicrographs displaying immunofluorescence for GH-R and neuroblasts in the ipsilateral SVZ at 5 days after HI at P21	122
<b>Figure 4.12</b> Validation of real time PCR products on a 1% agarose gel	123
<b>Figure 4.13</b> Representative amplification plots (A), dissociation curves (B) and a standard curve (C) obtained by real time PCR using GH-R primers	124
<b>Figure 4.14</b> Graphs depicting the effect of HI at P21 on the level of GH-R mRNA relative to that of cyclophilin A mRNA at 5 days after HI in the olfactory bulb (A), hippocampus (B), cortex (C) and SVZ (D)	125
<b>Figure 4.15</b> Validation of nestin real time PCR	126
<b>Figure 4.16</b> Level of nestin mRNA relative to that of cyclophilin A mRNA (A) and the correlation between nestin mRNA and GH-R mRNA levels (B) in the SVZ at 5 days after HI at P21	127
<b>Figure 4.17</b> Photomicrographs showing strong GH-R mRNA in the dentate gyrus (A) and paraventricular hypothalamus (C)	128
<b>Figure 4.18</b> Autoradiographs showing expression of GH-R mRNA in the liver (A), the forebrain of a P26 control animal (C) and at 5 days after HI at P21 (E,G,I)	129
<b>Figure 5.1</b> Schematic representation of the rat PRL-R gene	144
<b>Figure 5.2</b> Diagram depicting the cloning strategy to obtain one plasmid carrying one copy of each the short and long PRL-R fragments	145
<b>Figure 5.3</b> Characterization of real time PCR products on a 2% agarose gel	156
<b>Figure 5.4</b> Representative dissociation curves for template DNA and negative controls	157
<b>Figure 5.5</b> Typical amplification plots and standard curve obtained by real time PCR	158
<b>Figure 5.6</b> Relative level of Total PRL-R mRNA in rat brain (A) cortex and (B) hippocampus at various intervals after birth	159
<b>Figure 5.7</b> Comparison of the DNA sequence expected based on the known cDNA sequences of PRL-R Long and Short, the DNA sequence of pGEM® T Easy and the cloning strategy used (shown in the Query line) versus the actual DNA sequence of the vector (shown in the Sbjct line)	161
<b>Figure 5.8</b> Real time PCR quantification of equimolar concentrations of purified PRL-R Long and Short form PCR fragments	162
<b>Figure 5.9</b> Real time PCR quantification of a serially diluted fragment of vector DNA containing one copy each of PRL-R Long and Short form transcripts	163

<b>Figure 5.10</b> Real time PCR quantification of the levels of Long and Short form PRL-R mRNA in the rat brain cortex (A) and hippocampus (B) during late embryonic and early postnatal stages	165
<b>Figure 5.11</b> Scatter plots representing the correlation between the level of PRL-R Long form mRNA and Total PRL-R mRNA for each cortical (A) and hippocampal (B) sample.	166
<b>Figure 5.12</b> Amount of Long form PRL-R mRNA in the (A) cortex and (B) hippocampus expressed in molecules per milligram of tissue	168
<b>Figure 5.13</b> Real time PCR quantification of Long and Short form PRL-R mRNA in the ovary and liver of day 21 lactating female rats and in the choroid plexus of P21 male rat pups	170
<b>Figure 5.14</b> Real time PCR standard curves used to quantitate PRL mRNA in (A) cortex and (B) hippocampus from early postnatal rat brain	174
<b>Figure 6.1</b> Detection of cDNA reverse transcribed from mRNA encoding human prolactin receptor long form (hPRL-R <sub>L</sub> ; A) and glyceraldehyde-3-phosphate dehydrogenase (hGAPDH; B)	201
<b>Figure 6.2</b> Detection of human PRL mRNA in MCF-7 cells and human neuroblastoma cell lines SK-N-MC (A) and SK-N-SH-SY5Y (SY5Y) (B, C)	202
<b>Figure 6.3</b> Semi-quantitation of (A) hPRL mRNA and (B) hGAPDH mRNA in SK-N-MC cells cultured in the absence of serum for 0, 24 or 48 hours	202
<b>Figure 6.4</b> Detection of mouse mRNA encoding prolactin (PRL), prolactin receptor (PRL-R) long form (PRL-R <sub>L</sub> ), PRL-R short isoforms 1, 2 and 3 (PRL-R <sub>S1</sub> , PRL-R <sub>S2</sub> and PRL-R <sub>S3</sub> ) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in adult mouse neural stem cells cultured as neurospheres	203
<b>Figure 6.5</b> DNA sequence of the extraneous 177 bp amplicon obtained when PCR for the long PRL-R isoform was performed on mouse neurospheres	203
<b>Figure 6.6</b> Effect of 48 hour treatment of SK-N-MC cells with FGF-2, IGF-I or a combination of both on prolactin receptor (long isoform) mRNA level (A) relative to that of GAPDH (B)	205
<b>Figure 6.7</b> Human neuroblastoma SK-N-MC cells differentiated for 72 hours with FGF-2 and IGF-I, then stained for GAP-43 and PRL-R	207
<b>Figure 6.8</b> Effect of various concentrations of all-trans-retinoic acid on cell growth over 72 hours as measured by MTT assay	208
<b>Figure 6.9</b> Representative images of SK-N-SH-SY5Y cells treated with various concentrations of all-trans-retinoic acid (indicated at left) for different lengths of time	210
<b>Figure 6.10</b> Validation of real time PCR primers designed to detect hPRL and hPRL-R <sub>L</sub> mRNA	212
<b>Figure 6.11</b> Effect of 48 hour retinoic acid treatment of SK-N-SH-SY5Y cells on (A) PRL-R <sub>L</sub> (B) GAP-43 and (C) $\beta$ -III-tubulin mRNA levels relative to those of GAPDH	213
<b>Figure 6.12</b> SK-N-SH-SY5Y cells cultured in the absence (A-C; J) or presence (D-I; K) of 50 $\mu$ M retinoic acid for 48 hours immunostained for GAP-43 and PRL-R (A-I) or GAP-43 and $\beta$ -III-tubulin (J & K)	215
<b>Figure 6.13</b> Box plots illustrating the effect of 20 nM PRL on the number of cells within each field after 3 days in differentiation medium	217
<b>Figure 6.14</b> Confocal photomicrographs displaying representative images of mouse neural stem cells differentiated for 3 days (A-D) and 7 days (E&F) in the absence (A,C,E) or presence (B,D,F) of 20 nM PRL, then stained for GFAP (green), neuronal markers (red) and nuclei (blue)	218

<b>Figure 6.15</b> Effect of 20 nM PRL on the total length of neurites per neuron after cells were differentiated for 7 days	220
<b>Figure 6.16</b> Histograms representing the frequency of primary processes (A) and secondary processes (B) of neurons cultured in the absence (control) or presence of 20 nM prolactin (PRL)	221
<b>Figure 6.17</b> Photomicrographs of neurons cultured in the absence (A,C,E) and presence (B,D,F) of 20 nM rmPRL	223
<b>Figure 6.18</b> Specificity of goat anti-rat PRL-R primary antibody on rat fixed-frozen liver sections.	224
<b>Figure 6.19</b> Cells derived from mouse NSCs cultured in differentiation medium for 3 days and immunostained for $\beta$ -III-tubulin and PRL-R	225

## List of Tables

<b>Table 3.1</b> Effect of weight at P3 on rate of damage seen in survivors of HI and on mortality rate. _____	84
<b>Table 3.2</b> Percentage of turns towards the left (anti-clockwise) during negative geotaxis (average of two tests). _____	89
<b>Table 3.3</b> Results of Surface Righting test _____	89
<b>Table 3.4</b> Results of the sham pups versus control pups in the Elevated Body Swing Test (EBST) at 2 hours, 1 day and 3 days after HI _____	91
<b>Table 4.1</b> Sequences and sources of primers used for conventional reverse transcriptase PCR (G6PDH) and real time PCR (GH-R; CYC A) _____	108
<b>Table 4.2</b> Source of cDNA, serial dilution factor and number of dilutions of cDNA used to create each real time PCR standard curve _____	109
<b>Table 5.1</b> Sequences of PCR primers used in real time PCR _____	147
<b>Table 5.2</b> Dilution factor and number of points used to generate real time PCR standard curves _____	152
<b>Table 5.3</b> Real time PCR quantification of Long form PRL-R mRNA in the ovary and liver of day 21 lactating female rats, and in the cortex and hippocampus of P7 and P21 male rats, respectively _____	170
<b>Table 5.4</b> Real time PCR quantification of PRL-R Long and Short form mRNA from hippocampus samples originally dissected (Before) and from hippocampus samples dissected from coronal sections of the opposite hemisphere of the same brain after the choroid plexus had been carefully removed (After) _____	172
<b>Table 6.1</b> Sequences of PCR primers used to detect mRNA encoding mouse glyceraldehyde-3-phosphate dehydrogenase (mGAPDH), prolactin (mPRL) and prolactin receptor (mPRLR) isoforms _____	189
<b>Table 6.2</b> Sequences of Forward (F) and Reverse (R) PCR primers used to detect mRNA encoding human GAPDH (hGADPH), human prolactin (hPRL) and the long form of the human prolactin receptor (hPRLR-L) _____	190
<b>Table 6.3</b> Details of the primary antibodies used and the corresponding secondary antibodies used to reveal them _____	192
<b>Table 6.4</b> Sequences and sources of the Forward (F) and Reverse (R) primers used in real time PCR to quantitate levels of mRNA encoding prolactin (PRL), the long form of prolactin receptor (PRLR-L), growth-associated protein 43 (GAP-43), $\beta$ -III-tubulin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) _____	196
<b>Table 6.5</b> Source of cDNA, serial dilution factor and number of dilutions of cDNA used to create each real time PCR standard curve. _____	197
<b>Table 6.6</b> Effect of all-trans-retinoic acid on the average amount of cell growth (determined by MTT assay) over each 24 hour period _____	209
<b>Table 6.7</b> Effect of all-trans-retinoic acid concentration and treatment time on the total number of $\beta$ -III-tubulin immunopositive neurites greater than 50 $\mu$ m and 100 $\mu$ m and proportion of cells with neurites greater than 50 $\mu$ m. _____	211
<b>Table 6.8</b> Characteristics of the real time PCR standard curves used to assay levels of prolactin receptor (hPRL-R <sub>L</sub> ), prolactin (PRL), GAP-43, $\beta$ -III-tubulin and GAPDH mRNA in SK-N-SH-SY5Y cells treated with 0, 5 or 50 $\mu$ M retinoic acid for 48 hours _____	212
<b>Table 6.9</b> The 25 <sup>th</sup> , 50 <sup>th</sup> and 75 <sup>th</sup> percentile values for the number of astrocytes and neurons within each field. _____	217

<b>Table 6.10</b> The 25 <sup>th</sup> , 50 <sup>th</sup> and 75 <sup>th</sup> percentile values for the total length of neurites per neuron and the numbers of primary (1°) and secondary (2°) neurites after 3 days in culture	219
<b>Table 6.11</b> The 25 <sup>th</sup> , 50 <sup>th</sup> and 75 <sup>th</sup> percentile values for the numbers of primary (1°) and secondary (2°) neurites of neurons after 7 days in culture	222

## List of Abbreviations

AMPA	$\alpha$ -amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
ATP	Adenosine-5'-triphosphate
ATRA	all- <i>trans</i> -retinoic acid
bFGF	basal fibroblast growth factor
bp	base pairs
BSA	Bovine serum albumin
cDNA	complementary deoxyribonucleic acid
CNS	Central nervous system
cpm	counts per minute
CSF	Cerebrospinal fluid
Ct	threshold cycle
CYC A	Cyclophilin A
d	days
Da	Dalton
DAPI	4',6-diamidino-2-phenylindole
DAPI	4',6-diamidino-2-phenylindole
DCX	Doublecortin
DEPC	Diethyl pyrocarbonate
DNA	Deoxyribonucleic acid
dNTPs	deoxyribonucleotide triphosphates
DTT	dithiothreitol
E-	Embryonic day
EBST	Elevated body swing test
EGF	Epidermal growth factor
ELBW	Extremely low birth weight
FBS	Fetal bovine serum
FGF-2	Fibroblast growth factor-2/basal fibroblast growth factor
G6PDH	glucose-6-phosphate dehydrogenase
GAP-43	Growth associated protein 43
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GFAP	Glial fibrillary acidic protein
GH	Growth hormone
GHBP	Growth hormone binding protein
GH-R	Growth hormone receptor
GHRH	Growth hormone releasing hormone
GM	Germinal matrix
gw	Gestational weeks
h	Hours
HI	Hypoxia-ischemia
HIE	Hypoxic-ischemic encephalopathy
i.p.	intraperitoneal
IGF	Insulin-like growth factor
IGFBP	Insulin-like growth factor binding protein
IGF-IR	IGF-I receptor
IgG	Immunoglobulin G
IRS	Insulin receptor substrate

ISH	<i>in situ</i> hybridisation
IVH	Intraventricular hemorrhage
JAK	Janus kinase
JNK	Jun N-terminal kinase
KPBS	Potassium phosphate-buffered saline
KPBS-T	Potassium phosphate-buffered saline with 0.01% (v/v) Tween-20
LB	Luria broth
m-	mouse
MAP-2	Microtubule associated protein-2
MAPK	Mitogen-activated protein kinase
min	minutes
MRI	Magnetic resonance imaging
mRNA	messenger ribonucleic acid
MTT	thiazolyl blue tetrazolium bromide
NCBI	National Center for Biotechnology Information
NDS	Normal donkey serum
NeuN	Neuronal nuclei
NGS	Normal goat serum
NMDA	<i>N</i> -methyl-D-aspartate
NSC	Neural stem cell
NTE	Sodium chloride/Tris/EDTA buffer
P-	Postnatal day
PBGD	Porphobilinogen deaminase
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PI3K	Phosphoinositide 3-kinase
PKC	Protein kinase C
PPPDE	Permuted papain fold peptidases of dsRNA viruses and eukaryotes
PRL	Prolactin
PRL-R	Prolactin receptor
PVHI	Periventricular haemorrhagic infarction
PVL	Periventricular leukomalacia
RNA	Ribonucleic acid
RNS	Reactive nitrogen species
ROI	Region of interest
ROS	Reactive oxygen species
rpm	Revolutions per minute
SEM	Standard error of the mean
SGZ	Subgranular zone
SSC	Saline-sodium citrate
STAT	Signal transducer and activation of transcription
SVZ	Subventricular zone
TBE	Tris/Borate/EDTA buffer
TIDA	Tuberoinfundibular dopaminergic
TNF- $\alpha$	Tumour necrosis factor- $\alpha$
TRH	Thyrotropin releasing hormone
TSH	Thyroid stimulating hormone
v	versus
VLBW	Very low birth weight